by Jordana Choucair | Oct 12, 2021 | Life Sciences
A new Kaiser Family Foundation poll revealed that 83 percent of the public favors allowing the government to negotiate lower drug prices for Medicare and private insurance plans. Ninety-three percent of respondents agreed that even if the prices were lower drugmakers...
by Jordana Choucair | Oct 11, 2021 | Life Sciences
Merck & Co. and partner Ridgeback Biotherapeutics LP said they asked the FDA to authorize their COVID-19 antiviral pill, which curbed hospitalizations and deaths in a late-stage study. According to Merck CEO Robert Davis, the “extraordinary impact of this pandemic...
by Jordana Choucair | Oct 7, 2021 | Life Sciences
The World Health Organization endorsed the first vaccine to prevent malaria, the first step toward wider distribution of the shots in lower-income countries. The vaccine, made by GlaxoSmithKline PLC, is moderately effective and the first shot developed for any...
by Jordana Choucair | Oct 5, 2021 | Life Sciences
The FDA authorized two additional COVID-19 at-home tests in an effort to continue increasing the availability of at-home tests amid shortages. The agency granted Laboratory Corporation of America an Emergency Use Authorizations for fits combined home collection kit...
by Jordana Choucair | Oct 4, 2021 | Life Sciences
Johnson & Johnson plans to ask the FDA early this week to authorize a booster shot of its COVID-19 vaccine. Recent federal data shows that the 15 million Americans who got Johnson & Johnson’s one-dose vaccine may have less protection than those who...
by Jordana Choucair | Oct 1, 2021 | Life Sciences
Merck & Co. said its experimental antiviral pill to treat COVID-19 reduced the risk of hospitalization and death by nearly half in a clinical trial. The results prompted an independent monitoring board to recommend the study end early because of the promising...
Recent Comments